Hasil Pencarian - Panagiotis Malandrakis

Perbaiki Hasil
  1. 1
    Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals

    Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals oleh Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Aimilia D. Sklirou, Maria Gavriatopoulou, Harry Alexopoulos, Panagiotis Malandrakis, Ioannis P. Trougakos, Meletios A. Dimopoulos, Evangelos Terpos

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals

    Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals oleh Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Sentiljana Gumeni, Panagiotis Malandrakis, Eleni-Dimitra Papanagnou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events

    High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events oleh Evangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, Vangelis Karalis, Efrosyni Merkouri, Despina Fotiou, Maria Gavriatopoulou, Panagiotis Malandrakis, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

    Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222 oleh Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Zoi Evangelakou, Maria Gavriatopoulou, Maria S. Manola, Panagiotis Malandrakis, Despoina D. Gianniou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Prevalence of MGCS Among Patients With Monoclonal Gammopathies

    Prevalence of MGCS Among Patients With Monoclonal Gammopathies oleh Foteini Theodorakakou, Despina Fotiou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Vassiliki Spiliopoulou, Panagiotis Malandrakis, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA

    PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA oleh Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Maria Gavriatopoulou

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

    Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma oleh Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study

    Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study oleh Vassiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis

    Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis oleh Dimitris Papadopoulos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Zoi Evangelakou, Panagiotis Malandrakis, Maria S. Manola, Despoina D. Gianniou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A. Dimopoulos, Vangelis Karalis, Evangelos Terpos

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients

    Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients oleh Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Diamantis C. Sideris, Despina Fotiou, Christine‐Ivy Liacos, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Andreas Scorilas, Evangelos Terpos

    Diterbitkan 2024-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome

    Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome oleh Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Maria Roussou, Ioanna Dialoupi, Panagiotis Malandrakis, Foteini Theodorakakou, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY OF THE R-ISS STAGING

    P826: THE CIRCULAR RNA OF THE CHAPERONIN-CONTAINING TCP1 SUBUNIT 3 GENE (CIRC-CCT3) IS OVEREXPRESSED IN MULTIPLE MYELOMA AND PREDICTS A FAVORABLE PROGNOSTIC OUTCOME, INDEPENDENTLY... oleh Maria Papatsirou, Christos Kontos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Foteini Theodorakakou, Christine Liacos, Nefeli Mavrianou-Koutsoukou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Andreas Scorilas, Evangelos Terpos

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY

    P861: PERSISTENT BONE MARROW AND IMAGING MRD NEGATIVITY AS CRITERIA TO STOP LENALIDOMIDE MAINTENANCE FOLLOWING ASCT: PRELIMINARY RESULTS OF A SINGLE-CENTER PROSPECTIVE COHORT STUDY oleh Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis Kostopoulos, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Vassiliki Spiliopoulou, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Ourania Tsitsiloni, Meletios A. Dimopoulos, Evangelos Terpos

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY

    P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD ST... oleh Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A. Dimopoulos

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

    P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHAS... oleh Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A. Dimopoulos

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era

    Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era oleh Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Vassiliki Spiliopoulou, Rodanthi-Eleni Syrigou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Roussou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Evangelos Terpos

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals

    Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals oleh Evangelos Terpos, Vangelis Karalis, Ioannis Ntanasis-Stathopoulos, Filia Apostolakou, Sentiljana Gumeni, Maria Gavriatopoulou, Dimitris Papadopoulos, Panagiotis Malandrakis, Eleni-Dimitra Papanagnou, Eleni Korompoki, Efstathios Kastritis, Ioannis Papassotiriou, Ioannis P. Trougakos, Meletios A. Dimopoulos

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

    B03: SKELETAL-RELATED EVENTS AND ABNORMAL MRI PATTERN AT DIAGNOSIS ARE ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA oleh Evangelos Terpos, Nikolaos Kanellias, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Efstathios Kastritis, Vassilis Koutoulidis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Panagiotis Malandrakis, Tina Bagratuni, Maria Roussou, Lia A Moulopoulos, Meletios A Dimopoulos

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma

    ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma oleh Maria Papatsirou, Christos K. Kontos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Foteini Theodorakakou, Christine‐Ivy Liacos, Nefeli Mavrianou‐Koutsoukou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Andreas Scorilas, Evangelos Terpos

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma

    miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma oleh Maria-Alexandra Papadimitriou, Konstantinos Soureas, Aristea-Maria Papanota, Panagiotis Tsiakanikas, Panagiotis G. Adamopoulos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Gavriatopoulou, Diamantis C. Sideris, Efstathios Kastritis, Margaritis Avgeris, Meletios-Athanasios Dimopoulos, Evangelos Terpos, Andreas Scorilas

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: